Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.41 -1.86 (-5.00%)
Streaming Delayed Price Updated: 11:20 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
28 29 Next >
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
All signs are pointing toward its continued success. 
Via The Motley Fool
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions. 
Via The Motley Fool
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Viking Therapeutics
 
Via Benzinga
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
 
Via Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Viking Therapeutics Stock Plummeted After Soaring Today
Are we ready for the Great Obesity Drug Gold Rush of the 2020s? 
Via The Motley Fool
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes. 
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
The biotech reported strong weight loss for higher doses of its experimental obesity pill. 
Via Investor's Business Daily
MarketBeat Week in Review – 10/28 - 11/1
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment 
Via MarketBeat
Topics Artificial Intelligence Economy
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
An Overview of Viking Therapeutics's Earnings
 
Via Benzinga
Market Whales and Their Recent Bets on VKTX Options
 
Via Benzinga
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
Via MarketBeat
This High-Flying Stock Just Became a Better Buy
It might not be too late to get in on the party. 
Via The Motley Fool
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star. 
Via The Motley Fool
S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump
US benchmark equity averages rose on Friday as the market ended a three-day losing streak. 
Via Talk Markets
Topics Stocks
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug. 
Via The Motley Fool
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. 
Via Investor's Business Daily
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
Regardless of who wins the presidency, investors are better off focusing on top growth stocks. 
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Viking recently announced the results of an early-stage clinical trial for VK0214. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
Where Will Viking Therapeutics Be in 5 Years?
We could be witnessing the birth of a major player in the biotech industry. 
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
It's hard to go wrong with either company, but one is more appealing. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.